Products

IALEX is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. IALEX is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of IALEX in the subsequent prevention of rheumatic fever are not available at present.) Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only) Otitis media due to S. pneumoniae, staphylococci Skin and soft-tissue infections caused by staphylococci and/or streptococci Genitourinary tract infections, including acute prostatitis caused by E. coli, P. mirabilis, and Klebsiella sp. The effectiveness of IALEX in the treatment of bacterial infections of the brain and spinal column has not been established and IALEX is not indicated in these conditions.

Imigran FDT is used to relieve a migraine attack. It should not be used to prevent migraine attacks from occurring. Imigran FDT may be used for migraine headaches with or without what is known as 'aura'.

Imigran Mk II injection is used to relieve a migraine attack or cluster headache. It should not be used to prevent migraine attacks or cluster headaches from occurring. Imigran Mk II injection may be used for migraine headaches with or without what is known as 'aura'.

Imigran nasal spray is used to relieve a migraine attack. It should not be used to prevent migraine attacks from occurring. Imigran nasal spray may be used for migraine headaches with or without what is known as 'aura'.

Imulate is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.

Imulate is indicated for the prophylaxis of organ rejection in paediatric patients with a body surface area of ≥ 1.25 m² receiving allogeneic renal transplants

IMURAN is used as an immunosuppressant antimetabolite either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. IMURAN, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. IMURAN, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: severe rheumatoid arthritis; systemic lupus erythematosus; dermatomyositis/polymyositis; autoimmune chronic active hepatitis; pemphigus vulgaris; polyarteritis nodosa; autoimmune haemolytic anaemia; chronic refractory idiopathic thrombocytopenic purpura.

IMURAN is used as an immunosuppressant antimetabolite either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. IMURAN, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. IMURAN, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: severe rheumatoid arthritis; systemic lupus erythematosus; dermatomyositis/polymyositis; autoimmune chronic active hepatitis; pemphigus vulgaris; polyarteritis nodosa; autoimmune haemolytic anaemia; chronic refractory idiopathic thrombocytopenic purpura.

INDOCID is indicated in active stages of:

Indopril is used for treatment of hypertension and heart failure. It is also used in patients with established coronary artery disease who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

INDOSYL MONO lowers high blood pressure, a condition which doctors call hypertension.

Treatment of hypertension (high blood pressure).

Management of essential hypertension. It may be tried as a sole therapeutic agent in the treatment of mild to moderate hypertension. Normally INSIG is used as the initial agent in multiple drug regimens.

Treatment of pulmonary and extrapulmonary tuberculosis in combination with other antitubercular agents.

Treatment of angina pectoris (classic effort associated angina, chronic stable angina, vaso-spastic angina, variant angina, unstable angina and angina decubitus) and myocardial ischaemia due to ischaemic heart disease, and an aid in the management of left ventricular failure, either alone or as part of the syndrome of congestive heart failure. Sublingual - Prevention and treatment of angina pectoris and myocardial ischaemia due to ischaemic heart disease. Acute and chronic left ventricular failure, either alone or as part of the syndrome of congestive heart failure to improve cardiac performance and stabilise the patient's condition. Oral - Relief of angina pectoris. It is not intended to abort the acute anginal episode, but is useful in the prophylactic treatment of angina pectoris and myocardial ischaemia due to ischaemic heart disease. An aid in the management of left ventricular failure, either alone or as part of the syndrome of congestive heart failure.